Patients treated with matched therapies selected through biomarker or genetic testing can live longer. The Pancreatic Cancer Action Network (PanCAN) supports the National Comprehensive Cancer Network (NCCN) guidelines’ recommendations to obtain genetic testing for inherited mutations at diagnosis and for patients to undergo biomarker testing of their tumor tissue unless clinically contraindicated. PanCAN offers precision medicine information and resources for you and your patients.

MORE TREATMENT OPTIONS

Through our Know Your Tumor service, PanCAN will cover the cost of your patient’s genetic and tumor tissue biomarker testing by Tempus, a CLIA-certified laboratory. Tempus will provide you with a report, including information on both somatic and germline mutations, tumor burden (TMB) and microsatellite instability (MSI). The report includes treatment options, providing valuable insight to support your treatment decisions.

Treatment options are personalized to your patient and may include:

- Targeted therapy, which avoids the toxicity of multi-agent chemotherapy
- Appropriate clinical trials, including molecularly targeted solid tumor trials
- Off-label treatments that may be particularly effective for your patient’s specific tumor mutations
- Standard of care treatments

Hundreds of physicians from across the country have received Know Your Tumor reports for their patients. About 26% of patients’ tumors have been found to have at least one actionable alteration.

THE KNOW YOUR TUMOR PROCESS

1. Patient contacts PanCAN
   Patients must contact PanCAN Patient Services at 877-272-6226 to enroll in the service.

2. Tempus contacts physician
   Tempus will contact the patient’s physician with information and instructions to begin testing.

3. Tempus performs testing
   Upon receipt of the patient’s tumor and blood or saliva samples, Tempus will conduct genetic and tumor biomarker testing.

4. Physician receives report
   About 14 days from receipt of the patient’s tumor tissue, Tempus will email the report, including treatment options, to the patient’s physician.

For more information, visit pancan.org/knowyourtumor/hcp
To enroll your patients, have them contact us at 877.272.6226